Exploratory Study of Natural Killer Cells in Human Skin

Not Applicable

Completed

• Conditions: Psoriasis; Melanoma; Atopic Dermatitis; Graft Versus Host Disease; Contact Dermatitis; Lichen Planus
• Interventions: Other: Biopsy and sample of blood

• Registration Number: NCT00824889
• Lead Sponsor: Assistance Publique Hopitaux De Marseille

Brief Summary

Natural Killer (NK) cells play a unique role during innate immune responses as they are able to recognize and eliminate, without specific sensitization, tumors, microbe-infected cells as well as allogeneic cells.In a first time, we will characterize the tissue distribution, the phenotype and the effector functions of NK cells present in the human healthy skin.

Detailed Description

Then, we will define whether these parameters are qualitatively/ quantitatively modified in the following skin pathologies: a) atopic dermatitis; b) contact dermatitis; c) psoriasis ; d) lichen planus ; e) GVH (graft versus host disease) ; (f) melanoma.

Study Timeline

• Study First Submitted: 2009-01-13
• Study First Submitted QC: 2009-01-16
• Study First Posted: 2009-01-19
• Study Start: 2009-02
• Primary Completion: 2011-11
• Study Completion: 2011-11
• Status Verified: 2014-08
• Last Update Submitted: 2014-08-28
• Last Update Posted: 2014-08-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• Age ≥ 18 years.
• Consent obtained after healthy donor or patient information.
• Patients suffering from one of the following diseases: a) atopic dermatitis ; b) contact dermatitis; c) psoriasis ; d) lichen planus ; e) GVH ; f) melanoma.

Exclusion Criteria

• Age below 18,
• pregnant or breastfeeding women,
• persons under guardianship, persons without social security, prisoners, persons hospitalized without consent on the basis of French laws L. 3212-1 et L. 3213-1. Patients affected by HIV infection, AIDS, Hepatitis A, B or C infection.
• Neutropenia <1000/mm3.
• Thrombopenia <50 000/mm3.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
7	Biopsy and sample of blood	melanoma patient
3	Biopsy and sample of blood	contact dermatitis patient
5	Biopsy and sample of blood	lichen planus patient
2	Biopsy and sample of blood	atopic dermatitis patient
4	Biopsy and sample of blood	psoriasis patient
1	Biopsy and sample of blood	Healthy volunteer
6	Biopsy and sample of blood	GVH patient

Primary Outcome Measures

Name	Time	Method
In a first time, we will characterize the tissue distribution, the phenotype and the effector functions of NK cells present in the human healthy skin.	12 months

Secondary Outcome Measures

Name	Time	Method
To determine whether the eventual modifications detected in skin pathologies are correlated to qualitative/ quantitative alterations of NK cell subsets present in the peripheral blood.	12 months

Trial Locations

Locations (1)

Service de Dermatologie- Hopital Sainte Marguerite; 🇫🇷 Marseille, France